Details for Patent: 8,735,380

Which drugs does patent 8,735,380 protect, and when does it expire?

Patent 8,735,380 protects ELLA and is included in one NDA.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 8,735,380

Title:	Ulipristal acetate tablets
Abstract:	The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
Inventor(s):	Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee:	Laboratoire HRA Pharma (Paris, FR)
Application Number:	13/140,219
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,735,380
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 8,735,380

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Hra Pharma	ELLA	ulipristal acetate	TABLET;ORAL	022474-001	Aug 13, 2010	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,735,380

PCT Information
PCT Filed	December 08, 2009	PCT Application Number:	PCT/EP2009/066652
PCT Publication Date:	June 17, 2010	PCT Publication Number:	WO2010/066749

International Family Members for US Patent 8,735,380

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009326084
Brazil	PI0922796
Canada	2745084
China	102245173
China	105267168
Colombia	6400186